US Bancorp
RCUS icon

US Bancorp’s Arcus Biosciences RCUS Stock Holding History

US Bancorp’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.7K Buy
403
+26
+7% +$562 ﹤0.01% 3404
2025
Q4 		$8.98K Hold
377
– – ﹤0.01% 3371
2025
Q3 		$5.13K Sell
377
-17,606
-98% -$183K ﹤0.01% 3527
2025
Q2 		$146K Sell
17,983
-1,773
-9% -$15.1K ﹤0.01% 2219
2025
Q1 		$155K Buy
19,756
+12,869
+187% +$149K ﹤0.01% 2161
2024
Q4 		$103K Buy
6,887
+6,615
+2,432% +$108K ﹤0.01% 2388
2024
Q3 		$4.16K Sell
272
-1,790
-87% -$28.2K ﹤0.01% 3630
2024
Q2 		$31.4K Buy
2,062
+1,353
+191% +$21.8K ﹤0.01% 2878
2024
Q1 		$13.4K Sell
709
-7,952
-92% -$137K ﹤0.01% 3234
2023
Q4 		$165K Buy
8,661
+6,751
+353% +$108K ﹤0.01% 2105
2023
Q3 		$34.3K Sell
1,910
-1
-0.1% -$20 ﹤0.01% 2623
2023
Q2 		$38.8K Buy
1,911
+536
+39% +$10.2K ﹤0.01% 2625
2023
Q1 		$25.1K Buy
1,375
+328
+31% +$6.27K ﹤0.01% 2874
2022
Q4 		$21.7K Buy
1,047
+547
+109% +$15.1K ﹤0.01% 2954
2022
Q3 		$13K Buy
500
+31
+7% +$820 ﹤0.01% 3279
2022
Q2 		$12K Sell
469
-99
-17% -$2.42K ﹤0.01% 3313
2022
Q1 		$18K Buy
568
+277
+95% +$9.28K ﹤0.01% 3143
2021
Q4 		$12K Sell
291
-252
-46% -$9.78K ﹤0.01% 3359
2021
Q3 		$19K Buy
543
+444
+448% +$13.8K ﹤0.01% 3158
2021
Q2 		$3K Hold
99
– – ﹤0.01% 3756
2021
Q1 		$3K Hold
99
– – ﹤0.01% 3632
2020
Q4 		$3K Buy
+99
New +$2.4K ﹤0.01% 3514
2020
Q3 		– Sell
-44
Closed -$1K – 3821
2020
Q2 		$1K Buy
+44
New +$1.19K ﹤0.01% 3643
2019
Q3 		– Sell
-2,891
Closed -$23K – 3657
2019
Q2 		$23K Hold
2,891
– – ﹤0.01% 2825
2019
Q1 		$36K Buy
2,891
+645
+29% +$7K ﹤0.01% 2637
2018
Q4 		$25K Buy
2,246
+120
+6% +$1.4K ﹤0.01% 2730
2018
Q3 		$30K Buy
+2,126
New +$27.1K ﹤0.01% 2784

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

US Bancorp's RCUS Position: Q1 2026 in Review

US Bancorp increased its Arcus Biosciences (RCUS) stake by 6.9% in Q1 2026, buying an estimated $562 and bringing the position to 403 shares worth $8.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3404.

US Bancorp first reported a position in RCUS in Q3 2018 and has held it in 27 quarters since. The position peaked at $165K in Q4 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • US Bancorp held 403 shares of Arcus Biosciences worth $8.7K as of Q1 2026.
  • US Bancorp bought 26 Arcus Biosciences shares in Q1 2026, an estimated $562.
  • Arcus Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3404 holding.
  • US Bancorp first reported a position in Arcus Biosciences in Q3 2018 and has held it in 27 quarters since.
  • US Bancorp's Arcus Biosciences position peaked at $165K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.